Trevi Corp (TRVI) Cash Money per Share

Trevi Therapeutics (TRVI) maintains strong pricing power based on the uniqueness of Haduvio, while patent protection and FDA requirements create an insurmountable barrier for competitors. The cash per share history clearly illustrates liquidity, and the 2.11 metric confirms the current level of financial stability. Stable sales are ensured by the long-term need of patients for the therapy of chronic neurological pathologies.
Comprehensive metric breakdowns and analytics for Trevi Therapeutics Inc (TRVI)

To minimize risks when investing in the biotechnology sector, it is critical to assess the liquid value of shareholder equity. This indicator is calculated by dividing total cash reserves by the number of shares outstanding, and an analysis of actual cash per share confirms that Trevi Therapeutics (TRVI) possesses sufficient capital to fund its R&D processes until clinical trial results are obtained.